单中心1 648例费城染色体阴性骨髓增殖性肿瘤患者JAK2、CALR和MPL基因突变的临床意义
该单中心研究采用基因测序法检测1 648例费城染色体阴性MPN患者的JAK2V617F、JAK2外显子12、CALR外显子9及MPL外显子10突变,分析不同突变类型与临床参数的差异。结果显示不同MPN亚型驱动基因突变谱不同,JAK2V617F突变者发病年龄更高、白细胞和血红蛋白水平更高,CALR突变者血小板计数更高。
要点
- JAK2V617F总检出率82.8%,PV为92.7%、ET为78.1%、PMF为81.3%。
- CALR突变总检出率8.7%,ET为12.6%、PMF为12.1%;MPL总检出率0.6%。
- JAK2V617F组中位发病年龄61岁,高于突变阴性组42岁(P<0.001)。
核心结论
- 基因检测使MPN的诊断及预后判断有了更可靠的依据,不同MPN亚型基因突变的发生频率、分布情况不同,不同基因突变导致独特的临床表型。
研究设计与样本
- 单中心研究,采用基因测序法检测1 648例费城染色体阴性MPN患者JAK2V617F、JAK2基因12号外显子、CALR基因9号外显子及MPL基因10号外显子突变情况。
主要发现
- JAK2V617F突变总检出率为82.8%(1 364/1 648),PV为92.7%(471/508)、ET为78.1%(819/1 049)、PMF为81.3%(74/91)。
- JAK2基因12号外显子突变总检出率为0.5%(9/1 648),均为PV患者1.7%(9/508);CALR突变总检出率为8.7%(143/1 648),ET为12.6%(132/1 049)、PMF为12.1%(11/91);MPL突变总检出率为0.6%(10/1 648),ET为0.9%(9/1 049)、PMF为1.1%(1/91);未发现两种及以上基因突变共存病例。
- JAK2V617F突变组中位年龄61(15~95)岁,高于JAK2 12号外显子突变组49(33~62)岁及突变阴性组42(3~78)岁(P值均<0.001),与CALR突变组57(17~89)岁、MPL突变组59(22~71)岁比较差异无统计学意义(P>0.05)。
- JAK2V617F突变阳性组白细胞计数、血红蛋白浓度均高于CALR突变阳性及阴性组(P<0.05),与MPL突变阳性组比较仅表现为高白细胞计数(P=0.013);CALR突变组血小板计数高于JAK2V617F突变组[966(400~2 069)×10⁹/L对800(198~3 730)×10⁹/L,P<0.001]。
- 1 160例患者进行了有效染色体核型分析,CALR突变阳性与阴性患者异常核型检出率差异无统计学意义[9.8%(8/82)对7.4%(80/1 078),P=0.441];JAK2V617F突变阳性与阴性患者异常核型检出率差异无统计学意义[7.7%(75/971)对6.9%(13/189),P=0.688];CALR突变阳性组与JAK2V617F突变阳性组异常核型检出率差异无统计学意义[9.8%(8/82)对7.7%(75/971),P=0.512];7例JAK2基因12号外显子突变阳性及6例MPL基因突变阳性患者均未发现异常核型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the prevalences of JAK2, CALR and MPL gene mutations and the mutation types in patients with Philadelphia chromosome negative myeloproliferative neoplasms (MPNs) , and to compare their clinical characteristics of different mutation types with each other and mutation negative group. Methods: The mutations of JAK2 V617F, JAK2 gene at exon 12, CALR gene at exon 9 and MPL gene at exon 10 in 1 648 Ph negative MPNs patients were detected by direct sequencing. Results: ① The JAK2V617F mutation was found in 471 (92.7%) of 508 PV patients, 819 (78.1%) of 1 049 ET patients and 74 (81.3%) of 91 PMF patients respectively, with the total mutation rate as 82.8% (1 364/1 648) . The JAK2 exon12 mutation was found in 9 (1.7%) of 508 PV patients, none was found in ET or PMF patients, with the total mutation rate as 0.5% (9/1 648) . The CALR mutation was found in 132 (12.6%) of 1 049 ET patients and 11 (12.1%) of 91 PMF patients respectively, with the total mutation rate as 8.7% (143/1 648) ; the MPL mutation was found in 9 (0.9%) of 1 049 ET patients and 1 (1.1%) of 91 PMF patients respectively, with the total mutation rate as 0.6% (10/1 648) . The co-occurrence of any two types of driver gene mutations was not detected by direct sequencing. ②The median onset age of patients with JAK2V617F[61 (15-95) y] was significant higher than of with JAK2 exon12 mutation[49 (33-62) y] or without mutations[42 (3-78) y] (P<0.001) , but not for patients with CALR[57 (17-89) y] or MPL mutation[59 (22-71) y] (P>0.05) . Patients with JAK2V617F had higher white blood cell count and hemoglobin level (P<0.05) when compared with patients with CALR mutation or without mutations, or only significantly higher white blood cell count when compared with patients with MPL mutation (P=0.013) . The platelet count of patients with CALR mutation was significantly higher than of with JAK2V617F[966 (400-2 069) ×10(9)/L vs 800 (198-3 730) ×10(9)/L, P<0.001]. ③Karyotype analysis was conducted in 1 160 patients with MPNs, the rates of karyotype abnormality of patients with and without CALR mutation were 9.8% (8/82) and 7.4% (80/1 078) (P=0.441) respectively; The rates of karyotype abnormality of patients with and without JAK2V617F mutation were 7.7% (75/971) and 6.9% (13/189) (P=0.688) respectively. The incidence of karyotype abnormality of patients with CALR mutation was higher than of with JAK2V617F[9.8% (8/82) vs 7.7% (75/971) ] without statistically significant difference (P=0.512) . The karyotype analysis of 7 cases of JAK2 exon12 mutation and 6 ones with MPL gene mutation revealed normal karyotype. Conclusions: Driver gene mutations detection could ensure the diagnosis and prognosis judgment of MPN more reliable, different subtypes of MPNs had different profiles of driver gene mutations, the latter lead to unique clinical phenotype. 目的: 研究Ph染色体阴性的慢性骨髓增殖性肿瘤(MPN)患者JAK2、CALR及MPL基因突变情况,比较不同类型基因突变及突变阴性患者部分临床参数的差异。 方法: 采用基因测序法分别检测1 648例Ph阴性MPN患者JAK2V617F、JAK2基因12号外显子、CALR基因9号外显子及MPL基因10号外显子突变情况。 结果: ①JAK2V617F突变总检出率为82.8%(1 364/1 648),其中真性红细胞增多症(PV)为92.7%(471/508),原发性血小板增多症(ET)为78.1%(819/1 049),原发性骨髓纤维化(PMF)为81.3%(74/91);JAK2基因12号外显子突变总检出率为0.5%(9/1 648),均为PV患者[1.7%(9/508)];CALR基因突变总检出率为8.7%(143/1 648),其中ET为12.6%(132/1 049),PMF为12.1%(11/91);MPL基因突变总检出率为0.6%(10/1 648),其中ET为0.9%(9/1 049),PMF为1.1%(1/91)。未发现两种及以上基因突变共存病例。②JAK2V617F突变组中位年龄[61(15~95)岁]高于JAK2 12号外显子突变组[49(33~62)岁]及突变阴性组[42(3~78)岁](P值均<0.001),与CALR突变组[57(17~89)岁]、MPL突变组[59(22~71)岁]比较差异无统计学意义(P>0.05)。JAK2V617F突变阳性组白细胞计数、血红蛋白浓度均高于CALR突变阳性及阴性组(P<0.05),而与MPL突变阳性组比较仅表现为高白细胞计数(P=0.013);CALR突变组血小板计数高于JAK2V617F突变组[966(400~2 069)×10(9)/L对800(198~3 730)×10(9)/L,P<0.001]。③共1 160例患者进行了有效染色体核型分析,CALR基因突变阳性、阴性患者异常核型检出率差异无统计学意义[9.8%(8/82)对7.4%(80/1 078),P=0.441];JAK2V617F突变阳性、阴性患者异常核型检出率差异无统计学意义[7.7%(75/971)对6.9%(13/189),P=0.688]。CALR突变阳性组与JAK2V617F突变阳性组的异常核型检出率差异无统计学意义[9.8%(8/82)对7.7%(75/971),P=0.512]。7例JAK2基因12号外显子突变阳性及6例MPL基因突变阳性患者均未发现异常核型。 结论: 基因检测使MPN的诊断及预后判断有了更可靠的依据,不同MPN亚型基因突变的发生频率、分布情况不同,不同基因突变导致独特的临床表型。.
引用
- Li MY, Chao HY, Sun AN, et al. [Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28468090. doi:10.3760/cma.j.issn.0253-2727.2017.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。